Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion

Transfusion

Volumn 49, Issue 11, 2009, Pages 2454-2489

  Kleinman, Steven H ^a   Lelie, Nico ^a   Busch, Michael P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

BLOOD DONOR; BLOOD TRANSFUSION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION RISK; MATHEMATICAL MODEL; NONHUMAN; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS INFECTIVITY; VIRUS TRANSMISSION;

BLOOD TRANSFUSION; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL;

EID: 70449085441     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02322.x     Document Type: Review

References (139)

1. Kleinman S, Busch MP, Korelitz JJ, Schreiber GB. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev 1997 11 : 155.
2. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J Med 1996 334 : 1685 90.
3. Lackritz EM, Satten GA, Aberle-Grasse J, Dodd RY, Raimondi VP, Janssen RS, Lewis WF, Notari EP 4th., Petersen LR. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States [see comments]. New Engl J Med 1995 333 : 1721 5.
4. Glynn SA, Kleinman SH, Wright DJ, Busch MP the NHLBI Retrovirus Epidemiology Donor Study. International application of the incidence rate/window period model. [Editorial]. Transfusion 2002 42 : 966 72.
5. Seed CR, Cheng A, Ismay SL, Bolton WV, Kiely P, Cobain TJ, Keller AJ Virology Subcommittee of the National Donor and Product Safety Committee, Australian Red Cross Blood Service. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion 2002 42 : 1365 72.
6. Müller-Breitkreutz K. Results of viral marker screening of unpaid blood donations and probability of window period donations in 1997. Vox Sang 2000 78 : 149 57.
7. Busch MP. Transfusion-transmitted viral infections: building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis. Transfusion 2006 46 : 1624 40.
8. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005 45 : 254 64.
9. Lindbach S, Thorstensson R, Karlsson AC, von Sydow M, Flamholc L, Blaxhult A, Sönnerborg A, Biberfeld G, Gaines H. Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. AIDS 2000 14 : 2333 9.
10. Kleinman SH, Busch MP. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol 2006 36 Suppl : S23 29.
11. Weusten JJ, van Drimmelen AA, Lelie PN. Mathematical modeling of the risk of HBV, HCV, and HIV transmission by window phase donations not detected by NAT. Transfusion 2002 42 : 537 48.
12. Haase AT. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 2005 5 : 783 92.
13. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003 17 : 1871 9.
14. Zhu T, Corey L, Hwangbo Y, Lee JM, Learn GH, Mullins JI, McElrath MJ. Persistence of extraordinarily low levels of genetically homogeneous human immunodeficiency virus type 1 in exposed seronegative individuals. J Virol 2003 77 : 6108 16.
15. Glynn SA, Wright DJ, Kleinman SH, Hirschkorn D, Tu Y, Heldebrant C, Smith R Giachetti C, Gallarda J, Busch MP. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005 45 : 994 1002. (Pubitemid 40798792)
16. Zetolla NM, Pilcher CD. Diagnosis and management of acute HIV infection. Infect Dis Clin North Am 2007 21 : 19 48.
17. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, Lebedeva M, DeCamp A, Li D, Grove D, Self SG, Borrow P. Induction of a striking systemic cytokine cascade before peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009 83 : 3719 33.
18. Tabor E, Purcell RH, London WT, Gerety RJ. Use of and interpretation of results using inocula of hepatitis B virus with known infectivity titers. J Infect Dis 1983 147 : 531 4.
19. Barker LF, Murray R. Relationship of virus dose to incubation time of clinical hepatitis and time of appearance of hepatitis-associated antigen. Am J Med Sci 1972 263 : 27 33.
20. Fiebig EW, Heldebrant C, Smith RI, Conrad A, Delwart EL, Busch MP. Intermittent low-level viremia in very early primary HIV-1 infection. J AIDS 2005 39 : 133 7.
21. Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW, Peddada L, Smith R, Schreiber GB, Epstein JS, Nemo GJ, Busch MP. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003 43 : 788 98.
22. Ma M, Abel K, Rouorke T, Wang Y, Miller CJ. A period of transient viremia and occult infection precedes persistent viremia and antiviral immune responses during multiple low-dose intravaginal simian immunodeficiency virus inoculations. J Virol 2004 78 : 14048 52.
23. Ma M, Piatak M, Fritts L, Lu D, Busch M, Miller C. Transmission of simian immunodeficiency virus (SIV) by plasma collected before detectable viremia and relative infectivity in ramp-up versus chronic stages. Transfusion 2007 47 : 17A 18A (abstract).
24. Ma ZM, Stone M, Piatak M Jr., Schweighardt B, Haigwood NL, Montefiori D, Lifson JD, Busch MP, Miller CJ. High specific infectivity of plasma virus from the pre-ramp up and ramp up stages of acute SIV infection. J Virol 2009 83 : 3288 97.
25. Shata MT, Tricoche N, Perkus M, Tom D, Brotman B, McCormack P, Pfahler W, Lee DH, Tobler LH, Busch M, Prince AM. Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees. Virology 2003 314 : 601 16.
26. Guidotti LG, Ando K, Hobbs MV, Ishikawa T, Runkel L, Schreiber RD, Chisari FV. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A 1994 91 : 3764 8.
27. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, Chisari FV. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003 77 : 68 76.
28. Mizukoshi E, Eisenbach C, Edlin BR, Newton KP, Raghuraman S, Weiler-Normann C, Tobler LH, Busch MP, Carrington M, McKeating JA, O'Brien TR, Rehermann B. Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis 2008 198 : 203 12.
29. Thurairajah PH, Hegazy D, Chokshi S, Shaw S, Demaine A, Kaminski ER, Naoumov NV, Cramp ME. Hepatitis C virus (HCV)-specific T cell responses in injection drug users with apparent resistance to HCV infection. J Infect Dis 2008 198 : 1749 55.
30. Fang CT, Tober LH, Haesche C. Fluctuation of HCV viral load before seroconversion in a healthy volunteer blood donor. Transfusion 2003 43 : 541 4.
31. Mosley JW, Operskalski EA, Tobler LH, Buskell ZJ, Andrews WW, Phelps B, Dockter J, Giachetti C, Seeff LB, Busch MP Transfusion-transmitted Viruses Study and Retrovirus Epidemiology Donor Study Groups. The course of hepatitis C viraemia in transfusion recipients before availability of antiviral therapy. J Viral Hepat 2008 15 : 120 8.
32. Busch MP. Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of donors and recipients. Transfus Clin Biol 2001 8 : 200 6.
33. Voght M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, Wiebecke B, Langer B, Meisner H, Hess J. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood donor screening. N Engl J Med 1999 341 : 866 70.
34. Lelie PN, van Drimmelem HA, Cuypers HT, Best SJ, Stramer SL, Hyland C, Allain JP, Moncharmont P, Defer C, Nübling M, Glauser A, da Silva Cardoso M, Viret JF, Lankinen MH, Grillner L, Wirthmüller U, Coste J, Schottstedt V, Masecar B, Dax EM. Sensitivity of HCV RNA and HIV RNA blood screening assays. Transfusion 2002 42 : 527 36.
35. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable viral control in the absence of antiretroviral therapy. Immunity 2007 27 : 406 16.
36. Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, Lai J, Gandhi SK, Siliciano JD, Williams TM, Siliciano RF. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 2007 81 : 2508 18.
37. Hatano H, Delwart EL, Norris PJ, Lee TH, Dunn-Williams J, Hunt PW, Hoh R, Stramer SL, Linnen JM, McCune JM, Martin JN, Busch MP, Deeks SG. Evidence of ongoing viral replication in individuals who control HIV in the absence of antiretroviral therapy. J Virol 2009 83 : 329 35.
38. Hollinger FB. Vagaries of occult hepatitis B - simplified and amplified. Transfusion 2008 48 : 1001 26.
39. Liu CJ, Chen DS, Chen PJ. Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol 2006 36 Suppl : S33 S44.
40. Allain JP. Occult hepatitis B virus infection: implications in transfusion. Vox Sang 2004 86 : 83 91.
41. Allain JP. International collaborative study proposal for the characterization of occult hepatitis B infection identified by nucleic acid or anti-HBc screening. Vox Sang 2007 92 : 254 7.
42. Carreno V. Occult HCV infection: a new form of hepatitis C. World J Gastronterol 2006 12 : 6922 5.
43. Castillo I, Pardo M, Bartolome J, Ortiz-Movilla N, Rodríguez- Iñigo E, de Lucas S, Salas C, Jiménez-Heffernan JA, Pérez-Mota A, Graus J, López-Alcorocho JM, Carreño V. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004 189 : 7 14.
44. Lerat H, Hollinger FB. Hepatitis C virus (HCV) occult infection or occult HCV RNA detection? J Infect Dis 2004 189 : 3 6 (editorial).
45. Bernardin F, Tobler L, Williams JD, Busch M, Delwart E. Clearance of HCV RNA from the PBMC of blood donors who spontaneously or therapeutically control their plasma viremia. Hepatology 2008 47 : 1446 52.
46. Tabuchi A, Tanaka J, Katayama K, Mizui M, Matsukura H, Yugi H, Shimada T, Miyakawa Y, Yoshizawa H. Titration of hepatitis B infectivity in the sera of pre-acute and late acute phases of HBV infection: transmission experiments to chimeric mice with human liver repopulated hepatocytes. J Med Virol 2008 80 : 2064 8.
47. Candotti D, Grabarczyk P, Ghiazza P, Roig R, Casamitjana N, Iudicone P, Schmidt M, Bird A, Crookes R, Brojer E, Miceli M, Amiri A, Li C, Allain JP. Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains. J Hepatol 2008 49 : 537 47.
48. Zaaijer HL, Torres P, Ontanon A, Ponte LG, Koppelman MH, Lelie PN, Hemert FJ, Boot HJ. Multiple surface antigen mutations in 5 blood donors with occult hepatitis B virus infection. J Med Virol 2008 80 : 1344 9.
49. Brojer E, Grabarczyk P, Liszewski G, Mikulska M, Allain JP, Letowska M Polish Blood Transfusion Service Viral Study Group. Characteristics of HBV DNA +/HbsAg - blood donors in Poland identified by triplex NAT. Hepatology 2006 44 : 1666 74.
50. Montefiori DC. Role of complement and Fc receptors in the pathogenesis of HIV-1 infection. Springer Semin Immunopathol 1997 18 : 371 90.
51. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The challenge of HIV-1 subtype diversity. N Engl J Med 2008 358 : 1590 602.
52. McCutchan FE. Global epidemiology of HIV. J Med Virol 2006 78 Suppl : S7 S12.
53. Laskus T, Wilkinson J, Gallegos-Orozco JF, Radkowski M, Adair DM, Nowicki M, Operskalski E, Buskell Z, Seeff LB, Vargas H, Rakela J. Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology 2004 127 : 764 76.
54. Soriano V, Gomes P, Heneine W, Holguín A, Doruana M, Antunes R, Mansinho K, Switzer WM, Araujo C, Shanmugam V, Lourenço H, González-Lahoz J, Antunes F. Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. J Med Virol 2000 61 : 111 6.
55. de Silva TI, Cotton M, Rowland-Jones SL. HIV-2 the forgotten AIDS virus. Trends Microbiol 2008 16 : 588 95.
56. Kandathil AJ, Ramalingam S, Kannangai R, David S, Sridharin G. Molecular epidemiology of HIV. Indian J Med Res 2005 121 : 333 44.
57. Dufoort G, Couroucé AM, Ancelle-Park R, Bletry O. No clinical signs 14 years after HIV-2 transmission via blood transfusion. Lancet 1988 2 : 510 (letter).
58. Kannangai R, Shaji RV, Ramalingam S, Jesudason MV, Abraham OC, George R, Shanmugam AP, Schwartz DH, Sridharan G. HIV-2 Subtype Circulating in India (South). J Acquir Immune Defic Syndr 2003 33 : 219 22.
59. Gomes M, Lima-Alves C, Ribeiro N, Serrao R, Marques R, Mota-Miranda A. Epidemiological aspects of HIV-2 infection in Portugal. 2001 Abstract no. I-236]. Interscience Conference on Antimicrobial Agents and Chemotherapy (41st: 16 December 2001: Chicago, IL). [cited 2009 Jan 14]. Available from: URL: http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=102270323.html
60. Botas J, Tavares L, Carvalho C, Feliciano H, Antunes F. HIV-2 infection: some clinical and epidemiological aspects in Portugal. 1989 Abstract no. M.A.P.77] Int Conf AIDS. 04-09 June 1989; 5:90. [cited 2009 Jan 14]. Available from: URL: http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=102176126.html
61. Assal A, Barlet V, Deschaseaux M, Dupont I, Gallian P, Guitton C, Morel P, David B, De Micco P. Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201. Transfusion 2009 49 : 301 10.
62. Eholie S, Anglaret X. Commentary: decline of HIV-2 prevalence in West Africa: good news or bad news? Int J Epidemiol 2006 35 : 1329 30.
63. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005 42 : 962 73.
64. Echevarria JM, Avellon A Hepatitis B genetic diversity. J Med Virol 2006 78 Suppl : S36 42.
65. Holguin A, Lopez M, Molinero M, Soriano V. Performance of three commercial viral load assays, Versant Human Immunodeficiency Virus type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1 and NucliSens HIV-1 EasyQ v1.2, testing HIV-1 non-B subtypes and recombinant viruses. J Clin Microbiol 2008 46 : 2918 23.
66. Wilkinson DA, Operskalski EA, Busch MP, Mosley JW, Koup RA. A 32-bp deletion within the CCR5 locus protects against transmission of parenterally acquired human immunodeficiency virus but does not affect progression to AIDS-defining illness. J Infect Dis 1998 178 : 1163 6.
67. Piatak Jr M, Saag MS, Yang LC. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993 259 : 1749 54.
68. Rusert P, Fischer M, Joos B, Leemann C, Kuster H, Flepp M, Bonhoeffer S, Günthard HF, Trkola A. Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol. Virology 2004 326 : 113 29.
69. Galli R, Merrick L, Friesenhahn M, Ziermann R. Comprehensive comparison of the Versant HIV-1 RNA 3.0 (bDNA) and COBAS Amplicor HIV-1 Monitor 1.5 assays on 1,000 clinical specimens. J Clin Virol 2005 34 : 245 52.
70. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS. Low-level viremia persists for at least 7 years in patients on suppressive retroviral therapy. Proc Natl Acad Sci U S A 2008 105 : 3879 84.
71. Saldanha J, Heath A, Lelie N, Pisani G, Nubling M, Yu M. Calibration of HCV working reagents for NAT assays against the HCV international standard. The Collaborative Study Group. Vox Sang 2000 78 : 217 24.
72. Davis C, Heath A, Best S, Hewlett I, Lelie N, Schuurman R, Holmes H. Calibration of HIV-1 working reagents for nucleic acid amplification techniques against the 1st international standard for HIV-1 RNA. J Virol Methods 2003 107 : 37 44.
73. Busch MP, Tobler LH, Gerlich WH, Shaefer S, Giachetti C, Smith R. Very low level viremia in HCV infectious unit missed by NAT. Transfusion 2003 43 : 1173 4 (letter to editor).
74. Delwart EL, Kalmin ND, Jones TS, Ladd DJ, Foley B, Tobler LH, Tsui RC, Busch MP. First report of human immunodeficiency virus transmission via an RNA-screened blood donation. Vox Sang 2004 86 : 171 7.
75. Ling AE, Robbins KE, Brown TM, Dunmire V, Thoe SY, Wong SY, Leo YS, Teo D, Gallarda J, Phelps B, Chamberland ME, Busch MP, Folks TM, Kalish ML. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA 2000 284 : 210 4.
76. Ferreira MC, Nel TJ. Differential transmission of human immunodeficiency virus (HIV) via blood components from an HIV-infected donor. Transfusion 2006 46 : 156 7 (letter to editor).
77. Zanetti AR, Bodini U, Clerici M, Romano L, Paolini E, Biasin M, Amendola A, Velati C. Transfusion of red blood cells from an HIV-RNA-positive/anti-HIV- negative donor without HIV infection in the recipient. Transfusion 2007 47 : 1328 9 (letter to editor).
78. Stramer S, Chambers L, Page PL, Wagner AG, Gibble J. Third reported case of breakthrough HIV transmission from NAT screened blood. Transfusion 2003 43 : 40 41A (abstract).
79. Phelps R, Robbins K, Liberti T, Machuca A, Leparc G, Chamberland M, Kalish M, Hewlett I, Folks T, Lee LM, McKenna M. Window-period human immunodeficiency virus transmission to two recipients by an adolescent blood donor. Transfusion 2004 44 : 929 33.
80. Najiouallah F, Barlet V, Renaudier P, Guitton C, Crova P, Guérin JC, Peyramond D, Trabaud MA, Coudurier N, Tardy JC, André P. Failure and success of HIV tests for the prevention of HIV-1 transmission by blood and tissue donations. J Med Virol 2004 73 : 347 9.
81. Harritshoj L, Dickmeiss E, Jorgensen L, Gerstsoft J, Hansen M, Ullum H. Transfusion-transmitted HIV infection by a Danish blood donor with a very low viral load in the pre-seroconversion window period. Transfusion 2008 48 : 2026 8 (letter to editor).
82. Schmidt M, Korn K, Nubling M, Chudy M, Kress J, Horst HA, Geusendam G, Hennig H, Sireis W, Rabenau HF, Doerr HW, Berger A, Hourfar MK, Gubbe K, Karl A, Fickenscher H, Tischer BK, Babiel R, Seifried E, Gürtler L. First transmission of HIV-1 by a cellular blood product after mandatory NAT blood screening in Germany. Vox Sang 2008 95 Suppl 1 : 56 (abstract).
83. Kalus U, Edelman A, Pruss A, Hofmann J, Kiesewetter H, Krüger DH, Salama A. Non-infectious transfusion of platelets donated before detection of HIV RNA in plasma. Transfusion 2009 49 : 435 9.
84. Kleinman S, van Drimmelen H, Lelie N, Busch M. Minipool NAT HIV 1 breakthrough transmission cases and probability of interdiction by current small pool or individual donation NAT screening systems. Vox Sang 2009 96 Suppl 1 : 3D-S23-03 : p53 (abstract).
85. Donegan E, Lenes BA, Tomasulo RA Mosley JW and the Transfusion Safety Study Group. Transmission of HIV-l by components type and duration of shelf storage before transfusion. Transfusion 1990 30 : 851.
86. Busch MP, Operskalski EA, Mosley JW, Lee TH, Henrard D, Herman S, Sachs DH, Harris M, Huang W, Stram DO. Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion. Transfusion Safety Study Group. J Infect Dis 1996 26 33.
87. Busch MP, Vermeulen M, Stramer SL. Rates and characterization of HIV elite controller (HIV-ab pos/HIV RNA-neg) donors: US and South Africa. Transfusion 2008 48 Suppl : 252A (abstract).
88. Murthy KK, Henrard DR, Eichberg JW, Cobb KE, Busch MP, Allain JP, Alter HJ. Redefining the HIV-infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission. Transfusion 1999 39 : 688 93.
89. Lee TH, Stromberg RR, Heitman JW, Sawyer L, Hanson CV, Busch MP. Distribution of HIV type 1 (HIV-1) in blood components: detection and significance of high levels of HIV-1 associated with platelets. Transfusion 1998 38 : 580 8.
90. Schüttler CG, Caspari G, Jursch CA, Willems WR, Gerlich WH, Shaefer S. Hepatitis C transmission by a blood donation negative in nucleic acid amplification tests for viral RNA. Lancet 2000 355 : 41 2 (letter to editor).
91. Taylor C, Price TH, Strong DM Possible HCV transmission from blood screened by pooled nucleic acid testing. Transfusion 2002 42 Suppl : 9S (abstract).
92. Grabarczyk P, Gronowska A, Brojer E, Letowska M, Radziwon P. Sequence analysis confirmation of transfusion-transmitted hepatitis C by red blood cells that tested negative by minipool hepatitis C virus nucleic acid testing. Transfusion 2007 47 : 1102 4 (letter to editor).
93. Kretzschmar E, Chudy M, Nubling CM, Ross RS, Kruse F, Trobish H. First case of hepatitis C virus transmission by a red blood cell concentrate after introduction of nucleic acid amplification technique screening in Germany: a comparative study with various assays. Vox Sang 2007 92 : 297 301.
94. Operskalski EA, Mosley JW, Tobler LH, Fiebig EW, Nowicki MJ, Mimms LT, Gallarda J, Phelps BH, Busch MP the Transfusion-Transmitted Viruses Study (TTVS) and the Retrovirus Epidemiology Donor Study (REDS). HCV viral load in anti-HCV-reactive donors and infectivity for their recipients. Transfusion 2003 43 : 1433 41.
95. Bernardin F, Tobler L, Walsh I, Williams JD, Busch M, Delwart E. Clearance of HCV RNA from the PBMC of blood donors who spontaneously or therapeutically control their plasma viremia. Hepatology 2008 47 : 1446 52.
96. Vermeulen M, Lelie N, Sykes W, Crookes R, Swanevelder J, Gaggia L, Le Roux M, Kuun E, Gulube S, Reddy R. Impact of Individual Donation (ID)-Nucleic Acid Testing (NAT) on risk of HIV, HBV and HCV transmission by blood transfusion in South Africa. Transfusion 2009;Feb 27. [Epub ahead of print].
97. Hijikata M, Shimizu YK, Kato H, Iwamoto A, Shih JW, Alter HJ, Purcell RH, Yoshikura H. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol 1993 67 : 1953 8.
98. Alter HJ, Sanchez-Pescador R, Urdea MS, Wilber JC, Lagier RJ, Di Bisceglie AM, Shih JW, Neuwald PD. Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. J Viral Hepat 1995 2 : 121 32.
99. Katayama K, Kumagia J, Komiya Y, Mizui M, Yugi H, Kishimoto S, Yamanaka R, Tamatsukuri S, Tomoguri T, Miyakawa Y, Tanaka J, Yoshizawa H. Titration of hepatitis C virus in chimpanzees for determining the copy number required for transmission. Intervirology 2004 47 : 57 64.
100. Busch MP, Murthy KK, Hirshkorn DF, Herring BL, Delwart EL, Racanelli V, Rehermann B, Alter HJ. Infectivity of donations from eclipse and ramp-up stages of HCV infection in chimpanzees. Transfusion 2007 47 Suppl : 17A (abstract).
101. Yu MW, Mason BL, Guo ZP, Tankersly DL, Nedjar S, Mitchell FD, Biswas RM. Hepatitis C transmission associated with intravenous immunoglobulins. Lancet 1995 345 : 1173 4 (letter to editor).
102. Roth WK. Hepatitis B and blood transfusion. ISBT Sci Ser 2007 2 : 178 83.
103. Comanor L, Holland P. Hepatitis B virus blood screening: unfinished agendas. Vox Sang 2006 91 : 1 12.
104. Gerlich WH, Wagner FF, Chudy M, Harritshoj LH, Lattermann A, Wienzek S, Glebe D, Saniewski M, Schuttler CG, Wend UC, Willems WR, Bauerfeind U, Jork C, Bein G, Platz P, Ullum H, Dickmeiss E. HBsAg non-reactive HBV infection in blood donors: transmission and pathogenicity. J Med Virol 2007 79 : S32 S36.
105. Chudy M, Schmidt M, Czudai V, Scheiblauer H, Nick S, Mosebach M, Hourfar MK, Seifried E, Roth WK, Grünelt E, Nübling CM. Hepatitis B virus genotype G monoinfection and its transmission by blood components. Hepatology 2006 44 : 99 107.
106. Matsumoto C, Tadokoro K, Fujimura K, Hirakawa S, Mitsunga S, Juji T. Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repository. Transfusion 2001 41 : 878 84.
107. Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, Tadokoro K. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007 47 : 1197 205.
108. Soldan K, Barbara JA, Dow BC. Transfusion-transmitted hepatitis B virus infection in the UK: a small and moving target. Vox Sang 2002 83 : 305 8.
109. Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ German Red Cross NAT Study Group. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus -1, hepatitis C virus, and hepatitis B virus. Transfusion 2008 48 : 1558 66.
110. Kleinman SH, Busch MP. Hepatitis B virus amplified and back in the blood safety spotlight. Transfusion 2001 41 : 1081 5 (editorial).
111. Hoofnagle JH, Waggoner JG. Hepatitis-A and hepatitis-B virus markers in immune serum globulin. Gastroenterology 1980 78 : 259 63.
112. Larsen J, Hetland G, Skaug K. Posttransfusion hepatitis B transmitted by blood from a hepatitis-B surface antigen-negative hepatitis-B virus carrier. Transfusion 1990 30 : 431 2.
113. Thiers V, Nakajima E, Kremsdorf D, Mack D, Schellekens H, Driss F, Goudeau A, Wands J, Sninsky J, Tiollais P, Brechot C. Transmission of hepatitis B from hepatitis B-seronegative subjects. Lancet 1988 2 : 1273 6.
114. Mosley JW, Stevens CE, Aach RD, Hollinger FB, Mimms LT, Solomon LR, Barbosa LH, Nemo GJ. Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients. Transfusion 1995 35 : 5 12.
115. Bremer CM, Saniewski M, Wend UC, Torres P, Lelie N, Gerlich WH, Glebe D. Transient occult hepatitis B virus infection in a blood donor with high viremia. Transfusion 2009;Apr 24. [Epub ahead of print].
116. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunological tolerance in utero? Proc Natl Acad Sci U S A 1990;87:6599-603.
117. O'Brien SF, Fearon MA, Yi QL, Fan W, Scalia V, Muntz IR, Vamvakas EC. Hepatitis B virus DNA-positive, hepatitis B surface-antigen negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience. Transfusion 2007 47 : 1809 15.
118. Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lleie N, Allain JP. Anti HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol 2008 48 : 1022 5.
119. Wendel S, Levi JE, Biagini S, Candotti D, Allain JP. A probable case of HBV transfusion transmission revealed after a 13-month-long window period. Transfusion 2008 48 : 1602 8.
120. Yoshikawa A, Gotanda Y, Minegishi K, Taira R, Hino S, Tadokoro K, Ohnuma H, Miyakawa K, Tachibana K, Misogushi H. Lengths of hepatitis B viremia and antigenemia in blood donors: preliminary evidence of occult (hepatitis B surface antigen-negative) infection in the acute stage. Transfusion 2007 47 : 1162 71.
121. Manzini P, Abate ML, Valpreda C, Milanesi P, Curti F, Rizzetto M, Smedile A. Evidence of acute primary occult hepatitis B virus infection in an Italian repeat blood donor. Transfusion 2009 49 : 757 64.
122. Linauts S, Saldanha J, Strong DM. Prism hepatitis surface antigen detection of hepatitis B virus minipool nucleic acid tasting yield samples. Transfusion 2008 48 : 1376 82.
123. Stramer SL, Foster G, Brodsky J, Alynteem K, Barr M, Dickson S, Harris W, Hrovat T, Krystof D, Parmeley M, Townsend R, Linnen J, Blunt J. Evaluation of the yield of HBV DNA-positive, seronegative donors using an automated HIV-1/HCV/HBV triplex NAT assay. Transfusion 2008 48 Suppl : 247A (abstract).
124. Gerlich WH. Breakthrough of hepatitis B virus escape mutants after vaccination and virus reactivation. J Clin Virol 2006 36 : S18 S22.
125. Wang JT, Lee CZ, Chen PJ, Wang TH, Chen DS. Transfusion-transmitted HBV infection in an endemic area: the necessity of more sensitive screening for HBV carriers. Transfusion 2002 42 : 1592 7.
126. Inaba S, Ito A, Miyata Y, Ishii H, Kajimoto S, Tanaka M, Maruta A, Saito S, Yugi H, Hino M, Tadokoro K. Individual nucleic amplification technology does not prevent all hepatitis B virus transmission by blood transfusion. Transfusion 2006 46 : 2028 9.
127. Komiya Y, Katayama K, Yugi H, Mizui M, Matsukura H, Tomoguri T, Tabuchi A, Tanaka J, Yoshizawa H. Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and C. Transfusion 2008 48 : 286 94.
128. Hsia CC, Purcell RH, Farshid M, Lachenbruch PA, Yu MY. Quantification of hepatitis B virus genomes and infectivity in human serum samples. Transfusion 2006 46 : 1829 35.
129. Prince AM, Lee DH, Brotman B. Infectivity of blood from PCR-positive, HBsAg-negative, anti-HBs-positive cases of resolved hepatitis B infection. Transfusion 2001 41 : 329 32.
130. Scullard GH, Greenberg HB, Smith JL, Gregory PB, Merigan TC, Robinson WS. Anti-viral treatment of chronic HBV infection: infectious virus cannot be detected in patient serum after permanent responses to treatment. Hepatology 1982 2 : 39 49.
131. Brummelhuis HG, Over J, Duivis-Vorst CC, Wilson-de Stürler LA, Ates G, Hoek PJ, Reerink-Brongers EE. Elimination of hepatitis B transmission by (potentially) infectious plasma derivatives. Vox Sang 1983 45 : 205 16.
132. Barrera JM, Francis B, Ercilla G, Nelles M, Achord D, Darner J, Lee SR. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 1995 68 : 15 8.
133. Courouce AM, Le Marrec N, Girault A, Ducamp S, Simon N. Anti-hepatitis C virus (anti-HCV) seroconversion in patients undergoing hemodialysis: comparison of second- and third-generation anti-HCV assays. Transfusion 1994 34 : 790 5.
134. Mimms LT, Mosley JW, Hollinger FB, Aach RD, Stevens CE, Cunningham M, Vallari DV, Barbosa LH, Nemo GJ. Transfusion-transmitted co-infection with human hepatitis B and hepatitis C viruses. BMJ 1993 307 : 1095 7.
135. Petersen LR, Satten GA, Dodd R, Busch M, Kleinman S, Grindon A, Lenes B the HIV Seroconversion Study Group. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. Transfusion 1994 34 : 283 9.
136. Busch MP, Lee LL, Satten GA, Henrard DR, Farzadegan H, Nelson KE, Read S, Dodd RY, Petersen LR. Time course of detection of viral and serological markers preceding HIV-1 seroconversion; implications for blood and tissue donor screening. Transfusion 1995 35 : 91 7.
137. Yoshikawa A, Gotanda Y, Itabashi M, Minegishi K, Kanemitsu K, Nishioka K Japanese Red Cross NAT Screening Research Group. Hepatitis B NAT virus-positive blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA. Vox Sang 2005 88 : 77 86.
138. Busch MP, Kleinman SH, Tobler LH, Kamel HT, Norris PJ, Walsh I, Matud JL, Prince HE, Lanciotti RS, Wright DJ, Linnen JM, Caglioti S. Virus and antibody dynamics in acute West Nile Virus infection. J Infect Dis 2008 198 : 984 93.
139. Humpe A, Legler TJ, Nubling CM, Riggert J, Unger G, Wolf C, Heermann KH, Köhler M. Hepatitis C virus transmission through quarantine fresh frozen plasma. Thromb Haemost 2000 84 : 784 8.